Sector Alpha Week of 2026-08-05
Sector Alpha — machine-written from the numbers · Data as of 2026-08-05

Ambarella, Inc.

AMBA
Technology · Semiconductor Equipment & Materials

Ambarella, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.

Biggest watch item: the price is already 2 weeks into its uptrend — timing risk, not thesis risk.

The price is in a confirmed uptrend (2 weeks in). Underneath, the last four quarters read improving. What settles it: the next one or two quarters of delivery.

Price
$82.2
+29.0% 1Y
Revenue (Apr 26)
$0.1 B
+11.1% YoY
Profit (Apr 26)
$−0.0 B
Operating margin
−20.0%
+13.3 pp YoY
ROE
−12%
FY26
ROIC
−23.9%
vs WACC 15.8% → −39.7 pp
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Ambarella, Inc. trades at $82.2, in a confirmed uptrend and 2 weeks into that stage. That is +16.7% against its own 200-day average. It sits at 81% of a 52-week range of $50 to $90. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 2 straight weeks.

Today the stock is in a confirmed uptrend — week 2 of stage 2. At $82.2 it trades +16.7% versus its 200-day average and sits at 81% of its 52-week range ($50–$90).

Aug 26: $82.2 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
+16.7% versus the 200-day line, week 2 of stage 2
Price50-day avg200-day avg
S1S4S3S2S1S2S1$93.6$79.4$65.3$51.2$37.1$$82$71Jul 23Apr 24Jan 25Oct 25Aug 26
S1S4S3S2S1S2S1$93.6$79.4$65.3$51.2$37.1$$82$71Jul 23Jan 25Aug 26
Beating or trailing, week by week since 2016 Each cell is one week from 2016 to now (527 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 16Aug 26

Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +53% while the S&P 500 moved +263% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 2 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

P/E does not price Ambarella, Inc. — earnings are negative, so there is no multiple to rank against its own history. The revenue and margin lines below are where a turn, when it comes, would show first. On sales the market values Ambarella, Inc. at 10.3× its FY26 revenue of $0.4 B.

With earnings negative, P/E does not price — there is no multiple to rank against its own history. The revenue and margin lines below are where the turn, when it comes, will show first.

PEG 16.36 PEG ratio per quarter — the P/E divided by the earnings-growth rate. The dashed line marks 1.0: below it the growth is cheap against the multiple, above it the price already prices the growth in. Last 19 quarters; values above 6 pinned at the top.
above 1.0, the multiple already banks the growth
PEGPEG = 1.0
6.4×5.0×3.5×2.0×0.6××6.00×Oct 21Oct 22Jan 24Jan 25Apr 26
6.4×5.0×3.5×2.0×0.6××6.00×Oct 21Jan 24Apr 26
P/E
earnings negative
PEG
n/m
not derivable — 3-year earnings growth unavailable

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: No read

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Ambarella, Inc. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 2 curves, on partial evidence.

Growth, year by year: revenue +39.3% in FY26 Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoY
45%24%3.4%−17%−38%%39.3%FY22FY24FY26
45%24%3.4%−17%−38%%39.3%FY22FY24FY26
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue rolling over
Revenue
75%46%17%−12%−41%%32.3%Jul 23Oct 24Apr 26
75%46%17%−12%−41%%32.3%Jul 23Oct 24Apr 26
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
−12%−16%−19%−22%−25%%−13.3%Jul 23Jan 24Oct 24Jul 25Apr 26
−12%−16%−19%−22%−25%%−13.3%Jul 23Oct 24Apr 26
Revenue growth
Rolling over
latest +32.3% · span −33.3% to +66.7%
ROCE
Rising
latest −13.3% · span −24.3%–−13.3%

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+39.3%+4.7%
Stock price+29.0%+2.6%−4.4%+3.4%
Revenue YoY (Apr 26)
+11.1%
latest quarter vs a year ago
Revenue 10y
4.3%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

44.2/100 — rank 19 of 29 in Semiconductor Equipment & Materials · 64% evidence confidence

Ambarella, Inc. scores 44.2 out of 100 against the 29 companies it is compared with in Semiconductor Equipment & Materials, ranking 19. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 22.3 + 3.5 + 10 + 8.4 = 44.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Ambarella, Inc. reported $0.1 B of revenue in the Apr 26 quarter, +11.1% year on year. That is the 7th straight quarter of year-on-year growth. Over 4 years it has compounded at 4.3% a year. The last full year, FY26, came in at $0.4 B. The last four reported quarters add to $0.4 B.

FY26 revenue came in at $0.4 B (+39.3% on the year), capping 4 years at 4.3% compound. The latest quarter (Apr 26) printed $0.1 B, +11.1% year on year — the 7th consecutive quarter of year-over-year growth.

FY26 revenue $0.4 B (+39.3% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
4.3% a year over 4 years
RevenueYoY growth
0.445%0.324%0.23.4%0.1−17%0.0−38%$ B%$0B39.3%FY22FY24FY26
0.445%0.324%0.23.4%0.1−17%0.0−38%$ B%$0B39.3%FY22FY24FY26
Apr 26: $0.1 B (+11.1% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
7th straight quarter of growth
Revenue (quarterly)YoY growth
0.1289%0.0955%0.0621%0.03−13%0.00−47%$ B%$0B11.1%Jul 23Oct 24Apr 26
0.1289%0.0955%0.0621%0.03−13%0.00−47%$ B%$0B11.1%Jul 23Oct 24Apr 26

Pace check: the last four quarters averaged +35.1% growth against the decade's 4.3% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +32.3% over the last 4 quarters against +39.7%/yr over the last 8 — rolling over.

06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Ambarella, Inc.'s operating margin is −20.0% in the Apr 26 quarter, +13.3 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −65.2% to −9.1%. The current quarter sits inside that band.

The latest quarter's operating margin is −20.0%, +13.3 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −65.2%–−9.1%.

Why the margin moved: operating margin went +13.3 pp year on year while gross margin went +4.4 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

FY26: −20.5% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
within a −65.2–−9.1% band over 5 years
operating marginYoY change (pp)
−4.6%32%−21%11%−37%−9.4%−53%−30%−70%−50%%%−20.5%25.9%FY22FY24FY26
−4.6%32%−21%11%−37%−9.4%−53%−30%−70%−50%%%−20.5%25.9%FY22FY24FY26
Apr 26: −20.0% operating margin (+13.3 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
−13%55%−31%25%−49%−4.1%−67%−34%−85%−63%%%−20%13.3%Jul 23Oct 24Apr 26
−13%55%−31%25%−49%−4.1%−67%−34%−85%−63%%%−20%13.3%Jul 23Oct 24Apr 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Ambarella, Inc. posted a net loss of $0.02 B in the Apr 26 quarter. The full FY26 year was a loss of $0.1 B. That loss is 20.0% of the quarter's revenue. The same quarter a year earlier lost $0.02 B. 12 of the last 12 reported quarters were loss-making.

Apr 26 profit was $−0.0 B, null year on year. On the full year, FY26 printed $−0.1 B (null).

FY26 profit $−0.1 B (null YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
Net profit
0.01−0.04−0.09−0.13−0.18$ B$−0BFY22FY24FY26
0.01−0.04−0.09−0.13−0.18$ B$−0BFY22FY24FY26
Apr 26: $−0.0 B (null YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)
0.00−0.01−0.03−0.05−0.06$ B$0BJul 23Oct 24Apr 26
0.00−0.01−0.03−0.05−0.06$ B$0BJul 23Oct 24Apr 26
08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Ambarella, Inc.'s cash-flow history is too thin to judge how much reported profit converts into cash. In FY26 that was $0.1 B of operating cash against $−0.1 B of profit. After $0.0 B of capital spending, $0.1 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.

FY26: operating cash of $0.1 B against reported profit of $−0.1 B, leaving free cash of $0.1 B after $0.0 B of capital spending.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY26: CFO $0.1 B vs profit $−0.1 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 5-year window, annual resolution.
Operating cashNet profitFree cash
0.090.02−0.05−0.12−0.19$ B$0B$−0B$0BFY22FY24FY26
0.090.02−0.05−0.12−0.19$ B$0B$−0B$0BFY22FY24FY26
Apr 26: operating cash $−0.0 B Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 12 quarters. Dashed line = 100%.
Operating cash (quarterly)100%
0.03101.2%0.02100.6%0.00100.0%−0.0299.4%−0.0398.8%$ B%$0BJul 23Oct 24Apr 26
0.03101.2%0.02100.6%0.00100.0%−0.0299.4%−0.0398.8%$ B%$0BJul 23Oct 24Apr 26

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Ambarella, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY26 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $0.0 B over the last 3 fiscal years.

FY26: capex $0.0 B Capital spending per fiscal year, $ B (bars).
steady investment
Capex
0.0220.0160.0110.0050.000$ B$0BFY22FY24FY26
0.0220.0160.0110.0050.000$ B$0BFY22FY24FY26
Apr 26: capex $0.0 B in the quarter Capital spending per quarter, $ B (bars, left); free cash flow, $ B (line, right). Last 12 quarters.
Capex (quarterly)Free cash
0.0110.030.0080.020.0050.000.003−0.020.000−0.03$ B$ B$0B$0BJul 23Oct 24Apr 26
0.0110.030.0080.020.0050.000.003−0.020.000−0.03$ B$ B$0B$0BJul 23Oct 24Apr 26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

Ambarella, Inc. earns a ROE of −14% in FY26. That is up from a trough of −30% in FY24. Return on invested capital clears the cost of that capital by −39.7 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −20.5% net margin on 0.49× asset turns.

FY26 ROE is −14%, recovered from a FY24 trough of −30% — the full ladder below shows the fall and the climb, undoctored.

🚨 Why the return is what it is — the wiring (FY26): −20.5% net margin × 0.49× asset turns × 1.36× balance-sheet leverage ≈ −13.7% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: −23.9% − 15.8% = a −39.7 pp spread. The 15.8% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

FY26: ROE −14% Return on equity by fiscal year, % (line); ROIC by fiscal year, % (line). 5-year window, dips included. Dashed line = the 15.8% cost of capital used on this page.
the climb back from FY24's −30%
ROEROIC (annual)WACC
21%2.7%−16%−34%−52%%−13.6%−27.8%FY22FY24FY26
21%2.7%−16%−34%−52%%−13.6%−27.8%FY22FY24FY26
Apr 26: ROIC −25.1% (TTM) vs WACC 15.8% Trailing-twelve-month ROIC and ROE, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROIC (TTM)ROE (TTM)WACC
21%1.7%−18%−37%−57%%−25.1%−12.1%Jul 23Oct 24Apr 26
21%1.7%−18%−37%−57%%−25.1%−12.1%Jul 23Oct 24Apr 26
11 · Dividend

Dividend

Ambarella, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.

Ambarella, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.

12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Ambarella, Inc. carries total debt of $0.0 B against shareholder equity of $0.6 B as of Apr 26, a debt-to-equity of 0.02 — effectively unlevered. On the annual view that ratio went from 0.02 in FY22 to 0.02 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Apr 26: total debt of $0.0 B against shareholder equity of $0.6 B — a debt-to-equity of 0.02. On the annual view, debt-to-equity went from 0.02 (FY22) to 0.02 (FY26). The returns on this page are earned, not borrowed.

FY26: debt $0.0 B at 0.02× equity Total debt by fiscal year, $ B (bars); debt-to-equity, × (line). 5-year window.
Total debtDebt-to-equity
0.0111.2×0.0080.6×0.0050.0×0.003−0.6×0.000−1.1×$ B×$0B0.02×FY22FY24FY26
0.0111.2×0.0080.6×0.0050.0×0.003−0.6×0.000−1.1×$ B×$0B0.02×FY22FY24FY26
Apr 26: debt $0.0 B, debt-to-equity 0.02 Total debt per quarter, $ B (bars); debt-to-equity, × (line). Last 12 quarters.
Total debt (quarterly)Debt-to-equity
0.0110.022×0.0080.016×0.0050.010×0.0030.004×0.000−0.002×$ B×$0B0.02×Jul 23Oct 24Apr 26
0.0110.022×0.0080.016×0.0050.010×0.0030.004×0.000−0.002×$ B×$0B0.02×Jul 23Oct 24Apr 26
13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

9.4% of Ambarella, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 2.2 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 9.4% of the float is sold short, and at typical trading volumes it would take about 2.2 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
9.4%
of the tradable float
Days to cover
2.2
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Ambarella, Inc.: the Z-score reads 9.25. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 9.25 sits well clear of the distress zone — the balance sheet is not the risk here.

The safety line in one sentence: the Z-score reads 9.25.

15 · Related companies · Semiconductor Equipment & Materials
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Teradyne, Inc.TER 69.6/100Thin evidence · provisional58% evidence TURNING 24.3/35 Revenue — · PAT — · OPM change 19.3 pp 45% evidence 18.4/25 ROCE 12.7% · OPM 36.9% 76% evidence 10.1/20 P/E 59.9× · PEG — 15% evidence 16.8/20 RS sector 5.5% · RS bench 40% · 1Y 275.3%7 of 12 weeks ahead 100% evidence
Exact sum: 24.3 + 18.4 + 10.1 + 16.8 = 69.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
2Applied Materials, Inc.AMAT 68.2/100Favorable setup85% evidence LEADER 22.1/35 Revenue 3.3% · PAT 25.9% · OPM change 1.4 pp 95% evidence 16.4/25 ROCE 8.9% · OPM 31.9% 76% evidence 11.1/20 P/E 39.2× · PEG 1.32 65% evidence 18.6/20 RS sector 7.8% · RS bench 44.6% · 1Y 195.7%12 of 12 weeks ahead 100% evidence
Exact sum: 22.1 + 16.4 + 11.1 + 18.6 = 68.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3Lam Research CorporationLRCX 63.8/100Thin evidence · provisional58% evidence FADING 21.9/35 Revenue — · PAT — · OPM change 1.9 pp 45% evidence 19.4/25 ROCE 15.5% · OPM 35% 76% evidence 9.6/20 P/E 65.8× · PEG — 15% evidence 12.9/20 RS sector -2.8% · RS bench 30.9% · 1Y 212.3%11 of 12 weeks ahead 100% evidence
Exact sum: 21.9 + 19.4 + 9.6 + 12.9 = 63.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
4ACM Research, Inc.ACMR 60.9/100Mixed-positive evidence81% evidence BREAKING OUT 17.6/35 Revenue 19.7% · PAT -9% · OPM change 0.6 pp 83% evidence 11.8/25 ROCE 2% · OPM 15.6% 76% evidence 14.7/20 P/E 30× · PEG 0.75 65% evidence 16.8/20 RS sector 2.7% · RS bench 38.8% · 1Y 244.7%11 of 12 weeks ahead 100% evidence
Exact sum: 17.6 + 11.8 + 14.7 + 16.8 = 60.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5ASML Holding N.V.ASML 56.1/100Mixed-positive evidence85% evidence FADING 22.6/35 Revenue 9.8% · PAT 13.5% · OPM change 2.5 pp 95% evidence 17.5/25 ROCE 11% · OPM 37.1% 76% evidence 4.7/20 P/E 63.3× · PEG 4.28 65% evidence 11.3/20 RS sector -15.3% · RS bench 18.8% · 1Y 137%9 of 12 weeks ahead 100% evidence
Exact sum: 22.6 + 17.5 + 4.7 + 11.3 = 56.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
6Kulicke and Soffa Industries, Inc.KLIC 55.0/100Thin evidence · provisional58% evidence FADING 23.2/35 Revenue — · PAT — · OPM change 20 pp 45% evidence 12.6/25 ROCE 4% · OPM 15.9% 76% evidence 9.8/20 P/E 61.6× · PEG — 15% evidence 9.4/20 RS sector -4.9% · RS bench 26.7% · 1Y 165%10 of 12 weeks ahead 100% evidence
Exact sum: 23.2 + 12.6 + 9.8 + 9.4 = 55 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
7FormFactor, Inc.FORM 54.6/100Thin evidence · provisional58% evidence ASLEEP 22.5/35 Revenue — · PAT — · OPM change 5.5 pp 45% evidence 12.7/25 ROCE 5.2% · OPM 7.4% 76% evidence 9.0/20 P/E 89.5× · PEG — 15% evidence 10.4/20 RS sector 1.3% · RS bench 30.9% · 1Y 320.9%7 of 12 weeks ahead 100% evidence
Exact sum: 22.5 + 12.7 + 9 + 10.4 = 54.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
8KLA CorporationKLAC 54.3/100Thin evidence · provisional58% evidence FADING 16.4/35 Revenue — · PAT — · OPM change -1.3 pp 45% evidence 18.2/25 ROCE 12.1% · OPM 41.2% 76% evidence 9.2/20 P/E 82.4× · PEG — 15% evidence 10.5/20 RS sector -15.5% · RS bench 16.9% · 1Y 113.7%10 of 12 weeks ahead 100% evidence
Exact sum: 16.4 + 18.2 + 9.2 + 10.5 = 54.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
9Cohu, Inc.COHU 52.8/100Thin evidence · provisional58% evidence FADING 20.1/35 Revenue — · PAT — · OPM change 19.3 pp 45% evidence 5.4/25 ROCE 0% · OPM -8.9% 76% evidence 9.9/20 P/E 60× · PEG — 15% evidence 17.4/20 RS sector 5.2% · RS bench 41.2% · 1Y 172.5%9 of 12 weeks ahead 100% evidence
Exact sum: 20.1 + 5.4 + 9.9 + 17.4 = 52.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
10AXT, Inc.AXTI 51.3/100Thin evidence · provisional58% evidence ASLEEP 22.1/35 Revenue — · PAT — · OPM change 47.2 pp 45% evidence 7.0/25 ROCE 1.7% · OPM -5.9% 76% evidence 8.5/20 P/E 3604× · PEG — 15% evidence 13.7/20 RS sector 36.7% · RS bench 50.9% · 1Y 2950%5 of 12 weeks ahead 100% evidence
Exact sum: 22.1 + 7 + 8.5 + 13.7 = 51.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
11Aehr Test Systems, Inc.AEHR 48.8/100Thin evidence · provisional58% evidence TURNING 15.7/35 Revenue — · PAT — · OPM change -34.9 pp 45% evidence 5.0/25 ROCE -0.7% · OPM -41% 76% evidence 11.5/20 P/E 12.4× · PEG — 15% evidence 16.6/20 RS sector 65.3% · RS bench 106.2% · 1Y 503.8%8 of 12 weeks ahead 100% evidence
Exact sum: 15.7 + 5 + 11.5 + 16.6 = 48.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
12Amkor Technology, Inc.AMKR 48.3/100Thin evidence · provisional58% evidence FADING 21.0/35 Revenue — · PAT — · OPM change 3.6 pp 45% evidence 12.5/25 ROCE 3% · OPM 6% 76% evidence 10.8/20 P/E 38.7× · PEG — 15% evidence 4.0/20 RS sector -23% · RS bench 4.2% · 1Y 141.5%8 of 12 weeks ahead 100% evidence
Exact sum: 21 + 12.5 + 10.8 + 4 = 48.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
13Amtech Systems, Inc.ASYS 48.2/100Thin evidence · provisional58% evidence FADING 20.5/35 Revenue -13.2% · PAT — · OPM change 211.5 pp 62% evidence 9.3/25 ROCE 2.5% · OPM 8.8% 76% evidence 9.3/20 P/E 68.7× · PEG — 15% evidence 9.1/20 RS sector -11.2% · RS bench 19.9% · 1Y 259.6%8 of 12 weeks ahead 70% evidence
Exact sum: 20.5 + 9.3 + 9.3 + 9.1 = 48.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
14Ichor Holdings, Ltd.ICHR 47.0/100Mixed-negative evidence64% evidence FADING 16.6/35 Revenue 7.6% · PAT — · OPM change 1.3 pp 62% evidence 5.8/25 ROCE 0.2% · OPM 0.8% 76% evidence 10.4/20 P/E 48.1× · PEG — 15% evidence 14.2/20 RS sector 20.6% · RS bench 48.4% · 1Y 308.7%11 of 12 weeks ahead 100% evidence
Exact sum: 16.6 + 5.8 + 10.4 + 14.2 = 47 · Decision use: Price leads the evidence: RS versus the benchmark is 48.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
15Nova Ltd.NVMI 46.4/100Mixed-negative evidence81% evidence ASLEEP 21.4/35 Revenue 21.4% · PAT 24.6% · OPM change 0.5 pp 83% evidence 15.7/25 ROCE 5.6% · OPM 30.1% 76% evidence 6.7/20 P/E 54.1× · PEG 2.56 65% evidence 2.6/20 RS sector -34.6% · RS bench -7.4% · 1Y 53%4 of 12 weeks ahead 100% evidence
Exact sum: 21.4 + 15.7 + 6.7 + 2.6 = 46.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
16Photronics, Inc.PLAB 45.4/100Mixed-negative evidence85% evidence ASLEEP 14.4/35 Revenue 0.5% · PAT 24.1% · OPM change -6.3 pp 95% evidence 13.8/25 ROCE 2.6% · OPM 20.1% 76% evidence 16.3/20 P/E 18.2× · PEG 0.43 65% evidence 0.9/20 RS sector -36.1% · RS bench -9.2% · 1Y 61.4%1 of 12 weeks ahead 100% evidence
Exact sum: 14.4 + 13.8 + 16.3 + 0.9 = 45.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
17Ultra Clean Holdings, Inc.UCTT 44.3/100Mixed-negative evidence64% evidence FADING 12.9/35 Revenue -3.2% · PAT -574.4% · OPM change -0.4 pp 62% evidence 6.6/25 ROCE 0.7% · OPM 2.1% 76% evidence 10.9/20 P/E 35.5× · PEG — 15% evidence 13.9/20 RS sector 11.3% · RS bench 40.5% · 1Y 264.4%11 of 12 weeks ahead 100% evidence
Exact sum: 12.9 + 6.6 + 10.9 + 13.9 = 44.3 · Decision use: Price leads the evidence: RS versus the benchmark is 40.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
18Onto Innovation Inc.ONTO 44.3/100Thin evidence · provisional56% evidence FADING 12.9/35 Revenue — · PAT — · OPM change -18.5 pp 39% evidence 9.9/25 ROCE 0.7% · OPM 5.2% 76% evidence 10.2/20 P/E 59.7× · PEG — 15% evidence 11.3/20 RS sector -5.6% · RS bench 27.8% · 1Y 179.5%8 of 12 weeks ahead 100% evidence
Exact sum: 12.9 + 9.9 + 10.2 + 11.3 = 44.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
19Ambarella, Inc.this pageAMBA 44.2/100Mixed-negative evidence64% evidence FADING 22.3/35 Revenue 27.8% · PAT — · OPM change 10.8 pp 71% evidence 3.5/25 ROCE -3.2% · OPM -19.3% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 8.4/20 RS sector -34.4% · RS bench 2.6% · 1Y 27.4%9 of 12 weeks ahead 100% evidence
Exact sum: 22.3 + 3.5 + 10 + 8.4 = 44.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
20InTest CorporationINTT 44.0/100Thin evidence · provisional58% evidence ASLEEP 19.5/35 Revenue -5.5% · PAT — · OPM change 13.6 pp 62% evidence 8.2/25 ROCE 0.8% · OPM 2.8% 76% evidence 8.6/20 P/E 341.3× · PEG — 15% evidence 7.7/20 RS sector -16.9% · RS bench 13.1% · 1Y 103.8%4 of 12 weeks ahead 70% evidence
Exact sum: 19.5 + 8.2 + 8.6 + 7.7 = 44 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
21Entegris, Inc.ENTG 42.6/100Mixed-negative evidence81% evidence ASLEEP 14.5/35 Revenue -0.3% · PAT -14.8% · OPM change 1.6 pp 83% evidence 10.9/25 ROCE 1.8% · OPM 17.4% 76% evidence 7.7/20 P/E 67× · PEG 1.93 65% evidence 9.5/20 RS sector -19% · RS bench 14.7% · 1Y 97.6%4 of 12 weeks ahead 100% evidence
Exact sum: 14.5 + 10.9 + 7.7 + 9.5 = 42.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
22Camtek Ltd.CAMT 39.3/100Mixed-negative evidence81% evidence ASLEEP 11.0/35 Revenue 10.6% · PAT -61.7% · OPM change -5.2 pp 83% evidence 13.5/25 ROCE 2.7% · OPM 22.4% 76% evidence 11.8/20 P/E 174.3× · PEG 0.8 65% evidence 3.0/20 RS sector -29.6% · RS bench -0.7% · 1Y 82.4%1 of 12 weeks ahead 100% evidence
Exact sum: 11 + 13.5 + 11.8 + 3 = 39.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
23IPG Photonics CorporationIPGP 39.2/100Mixed-negative evidence74% evidence ASLEEP 14.8/35 Revenue 9.2% · PAT — · OPM change -3.7 pp 62% evidence 6.8/25 ROCE -0.4% · OPM -2.9% 76% evidence 13.0/20 P/E 166.1× · PEG 0.67 65% evidence 4.6/20 RS sector -40.8% · RS bench -14% · 1Y 25%0 of 12 weeks ahead 100% evidence
Exact sum: 14.8 + 6.8 + 13 + 4.6 = 39.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
24Axcelis Technologies, Inc.ACLS 38.6/100Mixed-negative evidence81% evidence FADING 7.8/35 Revenue -11.8% · PAT -44.1% · OPM change -11.1 pp 83% evidence 9.8/25 ROCE 0.7% · OPM 4% 76% evidence 12.5/20 P/E 29× · PEG 1.16 65% evidence 8.5/20 RS sector -16% · RS bench 18.4% · 1Y 75.9%9 of 12 weeks ahead 100% evidence
Exact sum: 7.8 + 9.8 + 12.5 + 8.5 = 38.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
25Veeco Instruments Inc.VECO 37.1/100Mixed-negative evidence81% evidence FADING 6.8/35 Revenue -7.8% · PAT -64.1% · OPM change -10.2 pp 83% evidence 7.2/25 ROCE -0.2% · OPM -1.7% 76% evidence 13.7/20 P/E 89.1× · PEG 0.65 65% evidence 9.4/20 RS sector -8.9% · RS bench 25% · 1Y 128%9 of 12 weeks ahead 100% evidence
Exact sum: 6.8 + 7.2 + 13.7 + 9.4 = 37.1 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
26Daqo New Energy Corp.DQ 28.0/100Thin evidence · provisional58% evidence BASING 9.2/35 Revenue -22.8% · PAT — · OPM change -472.4 pp 62% evidence 4.4/25 ROCE -2.6% · OPM -564.4% 76% evidence 11.4/20 P/E 12.5× · PEG — 15% evidence 3.0/20 RS sector -68.5% · RS bench -48.5% · 1Y -36.8%0 of 12 weeks ahead 70% evidence
Exact sum: 9.2 + 4.4 + 11.4 + 3 = 28 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
27Trio-Tech InternationalTRT 53.0/100Thin evidence · provisional14% evidence 17.5/35 Revenue — · PAT — · OPM change — 0% evidence 12.5/25 ROCE — · OPM — 0% evidence 10.0/20 P/E — · PEG — 0% evidence 13.0/20 RS sector 0.1% · RS bench 43.9% · 1Y 259.6%8 of 8 weeks ahead to 2026-07-10 70% evidence
Exact sum: 17.5 + 12.5 + 10 + 13 = 53 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
28Qnity Electronics, Inc.Q 52.2/100Thin evidence · provisional38% evidence ASLEEP 16.7/35 Revenue — · PAT — · OPM change -0.4 pp 45% evidence 15.0/25 ROCE 4.2% · OPM 20.6% 76% evidence 10.5/20 P/E 45.2× · PEG — 15% evidence 10.0/20 RS sector — · RS bench — · 1Y —7 of 12 weeks ahead 0% evidence
Exact sum: 16.7 + 15 + 10.5 + 10 = 52.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
29Atomera IncorporatedATOM 43.8/100Thin evidence · provisional43% evidence FADING 21.8/35 Revenue — · PAT — · OPM change 79084.1 pp 39% evidence 4.9/25 ROCE -19.5% · OPM — 61% evidence 10.0/20 P/E — · PEG — 0% evidence 7.1/20 RS sector -20% · RS bench 6.9% · 1Y 60.5%8 of 12 weeks ahead 70% evidence
Exact sum: 21.8 + 4.9 + 10 + 7.1 = 43.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is Ambarella, Inc.'s stock price today?

Ambarella, Inc. trades at $82.2, +29.0% over the past year. The company is valued at $4.0 B. The stock sits at 81% of its 52-week range of $50–$90, +16.7% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 2 weeks in. — as of 5 August 2026.

What were Ambarella, Inc.'s latest quarterly results?

Ambarella, Inc. reported revenue of $0.1 B and a net loss of $0.0 B for the Apr 26 quarter. Earnings per share were $−0.41. The operating margin was −20.0%, 13.3 pp higher than a year earlier. — as of 5 August 2026.

What is Ambarella, Inc.'s revenue?

Ambarella, Inc. reported revenue of $0.1 B in the Apr 26 quarter, +11.1% year on year. For the full FY26 fiscal year, revenue was $0.4 B (+39.3%). Over the last 4 years revenue compounded at 4.3% a year. — as of 5 August 2026.

What is Ambarella, Inc.'s profit?

Ambarella, Inc. earned $−0.0 B of net profit in the Apr 26 quarter. Full-year FY26 profit was $−0.1 B. The operating margin ran −20.0% in the latest quarter. — as of 5 August 2026.

What is Ambarella, Inc.'s market cap?

Ambarella, Inc.'s market capitalisation is $4.0 B at a stock price of $82.2. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.

Does Ambarella, Inc. pay a dividend?

No — Ambarella, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.

How is Ambarella, Inc. performing?

Ambarella, Inc. is in a confirmed uptrend, 2 weeks in. Against the S&P 500 it has been ahead on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 5 August 2026.

Is Ambarella, Inc. in an uptrend?

Yes — the price is in a confirmed uptrend (week 2 of stage 2), trading +16.7% versus its 200-day average and at 81% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.

Is Ambarella, Inc. beating the market?

On recent form, yes — Ambarella, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 2 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +53% against the S&P 500's +263% — behind the index over the full window. — as of 5 August 2026.

Will Ambarella, Inc.'s stock price go up?

This page publishes no price forecast for Ambarella, Inc. What it measures instead: the stock price is $82.2, the price is in a confirmed uptrend 2 weeks in. Direction is not something this site claims to know. — as of 5 August 2026.

Is the market betting against Ambarella, Inc.?

Somewhat — short interest is 9.4% of Ambarella, Inc.'s tradable float, about 2.2 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.

Does Ambarella, Inc. have too much debt?

No — Ambarella, Inc.'s debt-to-equity is 0.02. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 5 August 2026.

What is Ambarella, Inc.'s capex?

Ambarella, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was $0.0 B. — as of 5 August 2026.

What is Ambarella, Inc.'s cash flow?

Ambarella, Inc. generated $0.1 B of operating cash flow in FY26 and $0.1 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $−0.1 B, so operating cash ran ahead of profit. — as of 5 August 2026.

How financially safe is Ambarella, Inc.?

On the balance sheet, the Z-score reads 9.25 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.

Where is Ambarella, Inc. in its business cycle?

Ambarella, Inc.'s FY26 operating margin was −20.5%, against a 5-year band of −65.2%–−9.1%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran −20.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.

What could break the Ambarella, Inc. story?

Biggest watch item: the price is already 2 weeks into its uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.

Is Ambarella, Inc. a stock worth studying right now?

This is not investment advice. The machine read: Ambarella, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI